-
Takeda's "Iatibant Acetate Injection" is about to be approved
Time of Update: 2021-04-27
However, in December 2020, Takeda's Ranarizumab was approved for marketing to prevent the onset of angioedema in HAE patients 12 years of age and older.
Today, Takeda's "Iatibant Acetate Injection" listing application has entered the administrative approval stage, which means that this type of patient may usher in the first acute treatment drug.
-
Fuan Pharmaceutical: Cefminox sodium for injection passed the consistency evaluation
Time of Update: 2021-04-27
, has recently received a supplementary drug application approval notice issued by the National Medical Products Administration, and its product Cefminox sodium for injection has passed The quality and efficacy consistency evaluation of generic drugs.
Cefminox sodium for injection is an anti-infective drug.
-
Shanghai passed local legislation: Chinese medicine is included in public health emergency management system
Time of Update: 2021-04-27
Encourage pharmaceutical manufacturers, operators of Chinese medicinal materials and Chinese medicinal pieces, medical institutions, and industry associations to establish an information traceability system in accordance with relevant laws, regulations and technical standards.
-
Hisun Pharmaceutical: Epirubicin Hydrochloride for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-04-27
On March 23, Hisun Pharmaceutical announced that the company's epirubicin hydrochloride for injection has passed the quality and efficacy consistency evaluation of generic drugs.
On May 5, 2019, the State Food and Drug Administration accepted the company's application for the consistency evaluation of epirubicin hydrochloride for injection.
-
Chengdu Better Pharmaceutical's Ampicillin Sodium for Injection has been successfully evaluated
Time of Update: 2021-04-27
On March 22, the official website of the State Food and Drug Administration showed that Chengdu Better Pharmaceutical's Ampicillin Sodium for injection successfully passed the evaluation, and it was the first in China; in addition, the company recently imitated the 4 types of dabigatran etexilate capsules.
-
China's first RET inhibitor, Cornerstone Pharmaceuticals, pratinib approved
Time of Update: 2021-04-27
CStone Pharmaceuticals announced today that NMPA has approved the marketing application of pratinib capsules for locally advanced or metastatic non-small cell lung cancer (NSCLC) that has previously received platinum-containing chemotherapy for transfection rearrangement (RET) gene fusion-positive non-small cell lung cancer (NSCLC) Treatment of adult patients.
-
The heads of the Ministry of Justice, the State Administration of Market Supervision, and the Food and Drug Administration answer questions from reporters on the Regulations on the Supervision and Administration of Medical Devices
Time of Update: 2021-04-27
Question: In 2017, the Central Office and the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Drugs and Medical Devices", proposing to promote the full implementation of the marketing authorization holder system.
-
"National Drug Sampling Inspection Annual Report (2020)" released
Time of Update: 2021-04-27
Medical Network, March 24 News On March 23, the website of China Food and Drug Control Institute released the "National Drug Sampling Inspection Annual Report (2020)" (hereinafter referred to as the
-
Ripretinib introduced by Zai Lab is approved for fourth-line treatment of gastrointestinal stromal tumors soon
Time of Update: 2021-04-27
In May 2020, the drug was approved by the FDA for the treatment of advanced gastrointestinal stromal tumors (GIST) who have been treated with three or more lysine kinase inhibitors (TKI) including imatinib ) An adult patient, with the trade name Qinlock, became the first approved fourth-line treatment for GIST.
-
Ganli Pharmaceutical's GZR18 clinical application was accepted by NMPA
Time of Update: 2021-04-27
For obesity and overweight indications, currently, no GLP-1 receptor agonist drug that is injected once a week has been approved for obesity and overweight treatment globally.
-
Eli Lilly’s business model adjustment for multinational pharmaceutical companies has a large number of drugs "patent cliff" here?
Time of Update: 2021-04-27
The CCO mixed line team is cancelled, what will happen to the patent expired drugs?In addition, in the email, Eli Lilly also stated, “During the business transformation and adjustment at the end of last year, based on the uncertain factors of the three products (Xinbaida, Cialy, and Futai), in order to smooth the business transition and explore uncertainties.
-
Qilu's two Class 1 new drugs are coming raging and target the 100 billion market
Time of Update: 2021-04-27
According to data from Minaiwang, since 2021, Qilu Pharmaceuticals has already approved two Class 2 improved new drugs for marketing, and three innovative drugs have been applied for clinical trials, of which two have been approved for clinical use.
-
CCTV Exposure: The price of Chinese medicine has risen again
Time of Update: 2021-04-27
cn/" target="_blank"> and regulations In addition, the publication of higher standards of the new version of the Pharmacopoeia is also conducive to the development of medicinal materials e-commerce.
-
Central Document: Four New Changes in the Development of Village Clinics
Time of Update: 2021-04-27
Rural revitalization cannot do without the support of rural medical and health services, and the improvement of rural doctors' medical and health services is inseparable The promotion of rural doctors' talent team is inseparable from the expansion and development of village-level medical institutions.
-
Luye Pharma's Class 1 new drug Ansufaxine Hydrochloride Sustained-Release Tablets reached the preset end point in Phase III clinical trials
Time of Update: 2021-04-27
The China Phase III clinical trial of LY03005 is a multi-center, randomized, double-blind, placebo-controlled study to verify the effectiveness and safety of LY03005 in the treatment of depression.
-
First-line treatment for advanced esophageal cancer: Can the domestic PD-1 eye-catching K drug sit on the top spot?
Time of Update: 2021-04-27
Following the three major clinical studies of Keynote-181, ATTRACTION-3, and ESCORT to establish the role and status of PD-1 monoclonal antibody in the second-line treatment of advanced esophageal squamous cell carcinoma, the release of the Keynote-590 study at the European Society of Medical Oncology (ESMO) in 2020 It directly brings the combination of immunotherapy and chemotherapy into the first-line treatment of advanced esophageal cancer.
-
Sanming Medical Reform makes headlines again!
Time of Update: 2021-04-27
MD, director of the annual salary of up to 60 Wan While drastically reducing the prices of medicines and consumables, Sanming has implemented a reform of changing cages for birds, greatly increasing medical service fees, and implementing an annual salary system for doctors.
-
Luoxin Pharmaceutical Subsidiary Omeprazole Sodium for Injection Passed the Consistency Evaluation
Time of Update: 2021-04-27
("Shandong Luoxin") had recently received the approval and issue of Ogilvy for Injection from the National Medical Products Administration.
The omeprazole sodium for injection developed by Shandong Luoxin was first approved for marketing in 2005.
-
Renhe Pharmaceuticals Entecavir Tablets Obtained Drug Registration Certificate
Time of Update: 2021-04-27
Entecavir tablets product indications are: This product is suitable for the treatment of chronic adult hepatitis B (including compensation and Patients with liver disease in decompensated stage).
-
Consumables in the eight regions of Henan have been bargained to start mass production
Time of Update: 2021-04-27
Medical Network News on March 25 Bargaining prices for supplies in eight regions On March 24, according to the news from Huazhao Equipment Network, the Xinxiang City Drugs and Medical Consumables Alliance Centralized Procurement Platform issued the "Notice on Online Quotations for the Centralized Procurement of Medical Consumables Alliance of Eight Cities (Counties) including Xinxiang City, Henan Province".
